Leerink Partnrs Issues Negative Forecast for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Investment analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Fulcrum Therapeutics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.35) per share for the quarter, down from their previous estimate of ($0.30). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at ($1.19) EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Several other research firms have also recently weighed in on FULC. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.63.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $3.59 on Friday. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The stock has a market cap of $193.64 million, a price-to-earnings ratio of -11.58 and a beta of 2.03. The firm’s 50 day moving average price is $4.11 and its two-hundred day moving average price is $4.57.

Institutional Investors Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at $38,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares during the last quarter. Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at $78,000. Walleye Capital LLC acquired a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at $59,000. Finally, Intech Investment Management LLC acquired a new position in Fulcrum Therapeutics during the 3rd quarter worth $62,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.